



Network Notification

Notice Date: June 13, 2019
To: West Virginia Marketplace Providers
From: CareSource
Subject: 2019 Behavioral Health HEDIS® IET Measures

Background

At CareSource, increasing numbers of West Virginians with alcohol and other drug (AOD) use problems are an important issue for us. The National Committee on Quality Assurance (NCQA) has added measures to the Health Effectiveness Data and Information Set (HEDIS) to measure the effectiveness and quality of care delivered by health plan provider networks in identifying and engaging members for AOD disorder treatment.

The 2019 Behavioral Health HEDIS Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) measure addresses the percentage of adolescent and adult members with a new episode of AOD disorder who receive the following:

- Initiation of AOD disorder treatment – the percentage of members who initiate through an inpatient AOD disorder admission, outpatient visit, intensive outpatient encounter, or partial hospitalization, telehealth or medication assisted treatment (MAT) within 14 days of the diagnosis.
- Engagement of AOD disorder treatment – the percentage of members who initiated treatment and who had two or more additional AOD disorder services or MAT **within 34 days of the initiation visit**.

Members for the IET Measure are identified solely through claims coming from any provider type. It is important that providers identify and code all AOD disorder diagnoses.

What can the provider do?

You can determine an AOD disorder diagnosis using the standard screening tool, screening for both alcohol and drug use. Please visit our SBIRT Provider Orientation, <https://www.caresource.com/documents/sbirt-provider-orientation/> to learn more about the screeners and evidence-based intervention shown to be effective for screening, providing brief interventions, and referral to treatment (SBIRT). You may also be eligible to bill for the SBIRT service in addition to the reason for your visit.

When a patient has an AOD disorder diagnosis, consider immediate referral to the behavioral health provider to start treatment **within 14 days of diagnosis**. If there are additional barriers that may impact accessing care, please contact CareSource member services at **1-855-202-0622** (TTY: 1-800-982-8771). To ensure the visit counts for the measure, notify the referring provider of the appropriate AOD disorder diagnosis code to be used for all follow-up member visits.

If you choose *not* to refer the patient to a behavioral health provider, you will need to schedule a visit at your office **within 14 days of the AOD disorder diagnosis date** to initiate AOD disorder treatment for the member.

- During the appointment have a supportive discussion and provide education and counseling to adolescents and their parents, pregnant women, and all adult members on the risks and health outcomes.

- Before the member leaves the appointment, schedule at least two additional follow-up visits for the patient, at your practice, **within 30 days of the initiation of treatment visit.**

Screening Resources

The following are evidence-based screening tools that can be used to identify AOD disorder:

- National Institute on Drug Abuse (NIDA) Drug Use Screening Tool
- Alcohol Use Disorders Identification Test (AUDIT)
- CAGE
- CAGE-AID
- CRAFFT
- Drug Screen Abuse Test (DAST-10)
- The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)

CareSource providers have the choice as to which validated screening tool to use to identify alcohol or another drug misuse. Information regarding development and validation of the evidence-based screening measures can be found in the Behavioral Health section of our website:

<https://www.caresource.com/wv/providers/education/patient-care/behavioral-health/marketplace/>

Medication Assisted Treatment (MAT)

- Alcohol Abuse or Dependence Medications: Disulfiram (oral), Naltrexone (oral and injectable), and Acamprosate (oral; delayed-release tablet)
- Opioid Abuse or Dependence Medication: Naltrexone (oral and injectable), Buprenorphine (sublingual tablet (PA), implant (PA) and subcutaneous injection (PA)), Buprenorphine/naloxone (sublingual tablet, buccal film (PA), sublingual film (PA))

Other Resources

- Substance Abuse and Mental Health Services Administration <https://www.samhsa.gov/>
- National Institute on Drug Abuse (NIDA) <https://www.drugabuse.gov/>
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) <https://www.niaaa.nih.gov/>

Screening, Brief Intervention and Referral to Treatment (SBIRT) <https://sbirt.clinicalencounters.com/>

Questions?

If you have any questions about these HEDIS measures, please contact Provider Services at **1-855-202-1091**.